PharmaCyte Biotech, Inc. (PMCB)

PharmaCyte Biotech Balance Sheet

Financials in millions USD. Fiscal year is May - April.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr 30, 2026	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022
Cash & Equivalents	18.6	15.17	50.18	68.04	85.4
Short-Term Investments	18.48	0.37	-	-	-
Cash & Short-Term Investments	37.08	15.54	50.18	68.04	85.4
Cash Growth	138.65%	-69.03%	-26.25%	-20.33%	3778.14%
Other Receivables	0.24	-	-	-	-
Receivables	0.24	3.7	-	-	-
Prepaid Expenses	0.1	0.22	0.26	0.11	0.09
Other Current Assets	-	2.92	-	-	-
Total Current Assets	37.42	22.38	50.44	68.15	85.49
Long-Term Investments	-	22.47	-	1.57	1.57
Other Intangible Assets	-	1.55	1.55	3.55	3.55
Other Long-Term Assets	9.33	8.77	7.91	0.01	0.01
Total Assets	46.75	55.17	59.9	73.28	90.62

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr 30, 2026	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022
Accounts Payable	0.27	0.4	0.39	0.13	0.21
Accrued Expenses	0.5	0.52	0.74	0.46	0.5
Other Current Liabilities	0.06	1.99	6.3	-	-
Total Current Liabilities	0.83	2.91	7.42	0.59	0.7
Other Long-Term Liabilities	10.95	0.36	12.97	-	-
Total Liabilities	11.77	3.28	20.39	0.59	0.7

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr 30, 2026	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022
Common Stock	0	0	0	0	0
Additional Paid-In Capital	182.72	181.49	185.33	202.23	201.58
Retained Earnings	-104.39	-84.97	-115.63	-115.96	-111.65
Treasury Stock	-45.01	-44.61	-42.04	-13.56	-
Comprehensive Income & Other	0.4	-0.02	-0.02	-0.02	-0.02
Total Common Equity	33.71	51.89	27.65	72.69	89.92
Shareholders' Equity	34.98	51.89	39.51	72.69	89.92
Total Liabilities & Equity	46.75	55.17	59.9	73.28	90.62

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr 30, 2026	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022
Net Cash (Debt)	37.08	15.54	50.18	68.04	85.4
Net Cash Growth	138.65%	-69.03%	-26.25%	-20.33%	3869.72%
Net Cash Per Share	4.43	2.12	5.24	3.49	5.50
Filing Date Shares Outstanding	10.74	6.8	7.71	8.78	20.75
Total Common Shares Outstanding	10.74	6.8	8.04	16.79	20.72
Working Capital	36.59	19.46	43.02	67.56	84.79
Book Value Per Share	3.14	7.64	3.44	4.33	4.34
Tangible Book Value	33.71	50.34	26.1	69.14	86.37
Tangible Book Value Per Share	3.14	7.41	3.25	4.12	4.17

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Apr 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 3, 2026

Data Sources Report a data error